Comparison 4. Rho kinase inhibitor + prostaglandin analog versus prostaglandin analog.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Mean IOP changes from baseline	4		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1.1 Netarsudil 0.02% + latanoprost 0.005% (FDC) once per day vs latanoprost 0.005% once per day	3	1114	Mean Difference (IV, Random, 95% CI)	‐1.64 [‐2.16, ‐1.11]
4.1.2 Ripasudil 0.4% twice per day + latanoprost 0.005% once per day vs latanoprost 0.005% once per day	1	205	Mean Difference (IV, Random, 95% CI)	‐0.29 [‐0.86, 0.28]
4.2 Total ocular adverse events (per person‐month) – incidence rate difference	4		Risk Difference (IV, Random, 95% CI)	0.26 [0.13, 0.40]
4.2.1 Netarsudil 0.02% + latanoprost 0.005% (FDC) once per day vs latanoprost 0.005% once per day	3		Risk Difference (IV, Random, 95% CI)	0.29 [0.11, 0.47]
4.2.2 Ripasudil 0.4% twice per day + latanoprost 0.005% once per day vs latanoprost 0.005% once per day	1		Risk Difference (IV, Random, 95% CI)	0.21 [0.11, 0.31]
4.3 Conjunctival hyperemia as adverse event (per person‐month)*	4		Risk Difference (IV, Random, 95% CI)	0.15 [0.03, 0.27]
4.3.1 Netarsudil 0.02% + latanoprost 0.005% (FDC) once per day vs latanoprost 0.005% once per day	3		Risk Difference (IV, Random, 95% CI)	0.10 [0.00, 0.20]
4.3.2 Ripasudil 0.4% twice per day + latanoprost 0.005% once per day vs latanoprost 0.005% once per day	1		Risk Difference (IV, Random, 95% CI)	0.24 [0.16, 0.32]
4.4 Ocular pain or irritation as adverse event (per person‐month)*	4		Risk Difference (IV, Random, 95% CI)	0.03 [‐0.00, 0.07]
4.4.1 Netarsudil 0.02% + latanoprost 0.005% (FDC) once per day vs latanoprost 0.005% once per day	3		Risk Difference (IV, Random, 95% CI)	0.05 [0.01, 0.09]
4.4.2 Ripasudil 0.4% twice per day + latanoprost 0.005% once per day vs latanoprost 0.005% once per day	1		Risk Difference (IV, Random, 95% CI)	‐0.02 [‐0.06, 0.02]